Want to see DMAC full AI Analyst Report?
DMAC Stock Chart & Stats
$6.85
-$0.24(-4.23%)
At close: 4:00 PM EST
$6.85
-$0.24(-4.23%)
Day’s Range― - ―
52-Week Range$3.48 - $10.42
Previous CloseN/A
Volume70.76K
Average Volume (3M)173.70K
Market Cap
$410.59M
Enterprise Value$304.10M
Total Cash (Recent Filing)$51.33M
Total Debt (Recent Filing)$212.00K
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 12, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding53,883,347
10 Day Avg. Volume189,843
30 Day Avg. Volume173,699
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.68
Forecast
1Y Price Target
$13.00Price Target Upside89.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical MomentumSustained, multicountry enrollment above 70% and an activated network of ~70 sites materially reduces execution risk and shortens time to an interim readout. A defined interim framework creates a clear binary milestone that can de‑risk the stroke program and inform go/no‑go decisions.
Conservative Balance SheetVery low leverage improves financial flexibility for a clinical‑stage biotech, lowering bankruptcy and solvency risk versus peers. A sizable equity base supports near-term funding needs and partnership negotiations even as losses persist, preserving optionality for development plans.
Near-term Funding RunwayA clear cash runway into 2027 gives management time to reach the planned interim analysis and multiple clinical readouts without immediate capital raises. This runway reduces short‑term dilution risk and allows strategic decision making on enrollment, partnerships, or resampling if needed.
Bears Say
No Commercial RevenueAbsence of product revenue means operations rely on financing rather than internal cash flow. Persistent, widening net losses translate directly into funding needs and investor dilution risk if clinical timelines slip or additional trials/resampling are required.
Rising Cash BurnQuarterly operating cash outflows and higher R&D (Q1 R&D $8.0M vs $5.7M prior‑year) indicate accelerating burn. Sustained increases in spend compress runway, raise the probability of future financings, and reduce runway for parallel programs absent milestone‑driven non‑dilutive funding.
U.S. Regulatory UncertaintyA failed rabbit study and FDA requests for more preclinical work introduce structural risk to U.S. trial timelines and approvals. Additional studies create cost, timing uncertainty and potential for further requests, which can delay U.S. development and commercial access materially.
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics’s price range in the past 12 months?
Diamedica Therapeutics lowest stock price was $3.48 and its highest was $10.42 in the past 12 months.
What is Diamedica Therapeutics’s market cap?
Diamedica Therapeutics’s market cap is $410.59M.
When is Diamedica Therapeutics’s upcoming earnings report date?
Diamedica Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 36 days.
How were Diamedica Therapeutics’s earnings last quarter?
Diamedica Therapeutics released its earnings results on May 06, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.004.
Is Diamedica Therapeutics overvalued?
According to Wall Street analysts Diamedica Therapeutics’s price is currently Undervalued.
Does Diamedica Therapeutics pay dividends?
Diamedica Therapeutics does not currently pay dividends.
What is Diamedica Therapeutics’s EPS estimate?
Diamedica Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Diamedica Therapeutics have?
Diamedica Therapeutics has 53,883,347 shares outstanding.
What happened to Diamedica Therapeutics’s price movement after its last earnings report?
Diamedica Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went up 0.153%.
Which hedge fund is a major shareholder of Diamedica Therapeutics?
Currently, no hedge funds are holding shares in DMAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (89.78% Upside)
$13.00 (89.78% Upside)
Blogger Sentiment
Bullish
DMAC Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
113.03%
12-Months-Change
Fundamentals
Return on Equity
-77.09%
Trailing 12-Months
Asset Growth
36.70%
Trailing 12-Months
Company Description
Diamedica Therapeutics
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
DMAC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress (stroke enrollment >70%, encouraging Phase II efficacy signals, Health Canada approval and active preeclampsia cohorts) and a clear pathway to multiple near-term clinical milestones through 2027. Financially, the company maintains a runway into 2027 but reported a quarter-over-quarter decline in cash, higher quarterly cash burn and materially higher R&D spend. Regulatory uncertainty in the U.S. (additional preclinical testing and an adverse rabbit study result) represents the primary risk to U.S. trial timelines. On balance, the clinical momentum and regulatory/operational achievements outweigh the financial and preclinical challenges at this stage.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$13.00
▲(89.78% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Rocket Pharmaceuticals
―
Benitec Biopharma
―
Annexon Biosciences
―
Ownership Overview
42.47% Insiders
2.86% Mutual Funds
― Other Institutional Investors
50.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---